Leuchte H H, Behr J, Ewert R, Ghofrani H A, Grünig E, Halank M, Held M, Klose H, Rosenkranz S, Schermuly R T, Wilkens H, Hoeper M M
Innere Medizin II, KH Neuwittelsbach, Akademisches Lehrkrankenhaus LMU, München.
Medizinische Klinik und Polklinik V, Klinikum der Universität München und Asklepios Fachkliniken München-Gauting, Comprehensive Pneumology Center, Mitglied des Deutschen Zentrums für Lungenforschung.
Pneumologie. 2015 Mar;69(3):135-43. doi: 10.1055/s-0034-1391435. Epub 2015 Mar 6.
Riociguat is the first clinically available soluble Guanylate-cyclase stimulator (sGC) and representative of a completely new class of drugs. Riociguat is approved for pulmonary arterial hypertension (PAH) and non-operable or recurrent/persistent chronic thromboembolic pulmonary hypertension (CTEPH). Moreover, Riociguat is currently under investigation for a wider spectrum of diseases. This article focusses on its mode of action and clinical trial data. Finally, based on these data, the status of approval, as well as the costs a proposal is given how Riociguat can be integrated in the current treatment of PAH and CTEPH.
利奥西呱是首个临床可用的可溶性鸟苷酸环化酶刺激剂（sGC），代表了一类全新的药物。利奥西呱已被批准用于治疗肺动脉高压（PAH）以及无法手术或复发/持续性慢性血栓栓塞性肺动脉高压（CTEPH）。此外，利奥西呱目前正在针对更广泛的疾病谱进行研究。本文重点关注其作用机制和临床试验数据。最后，基于这些数据，给出了利奥西呱的获批情况、成本，以及关于如何将其纳入PAH和CTEPH当前治疗方案的建议。
